Home Medicine Advances Article
PDF (885.5 KB)
Cite
EndNote(RIS) BibTeX
Collect
Submit Manuscript
Original Article | Open Access

Development of a local nomogram‐based scoring system for predicting overall survival in idiopathic pulmonary fibrosis: A rural appalachian experience

Rowida Mohamed1 (), Rahul G. Sangani2, Khalid M. Kamal3, Traci J. LeMaster3, Toni Marie Rudisill4, Virginia G. Scott3, George A. Kelley4,5, Sijin Wen4
Biological Sciences Division, University of Chicago, Chicago, Illinois, USA
Pulmonary and Critical Care Medicine, Northeast Georgia Health System, Gainesville, Georgia, USA
Department of Pharmaceutical Systems and Policy, School of Pharmacy, West Virginia University, Morgantown, West Virginia, USA
Department of Epidemiology and Biostatistics, School of Public Health, West Virginia University, Morgantown, West Virginia, USA
School of Public and Population Health and Department of Kinesiology, Boise State University, Boise, Idaho, USA
Show Author Information

Graphical Abstract

View original image Download original image
In our study, we developed a nomogram‐based risk‐staging system for idiopathic pulmonary fibrosis based on inpatient data from West Virginia University Medicine hospitals. We identified DLco%, body mass index (used as an indicator of malnutrition), pulmonary hypertension, pulmonary embolism, and sleep apnea as independent predictors of overall survival. Nomograms offer a reliable visualization of multivariable prognostic models.

Abstract

Background

Accurate staging systems are essential for assessing the severity of idiopathic pulmonary fibrosis (IPF) and guiding clinical management. This study aimed to evaluate the prognostic value of pulmonary comorbidities and body mass index (BMI) in IPF, develop a nomogram predicting overall survival (OS), and create a nomogram‐based survival prediction model.

Methods

Patients with IPF were identified from electronic medical records of the West Virginia hospital system. Least Absolute Shrinkage and Selection Operator (LASSO) Cox regression analysis was used for variable selection, and a nomogram was constructed. Risk groups were defined based on the nomogram's probability tertiles. The performance of the nomogram‐based model was evaluated using Harrell's concordance index (C‐index) and the Hosmer–Lemeshow test.

Results

The study included 152 patients with IPF. The majority of the patients were elderly, male, and had a BMI above 24 kg/m2. The median survival duration was 7.6 years. The survival rates were 91% at 1 year, 78% at 3 years, and 68% at 5 years. LASSO regression selected carbon monoxide lung diffusion capacity percentage predicted (DLco%), BMI, pulmonary hypertension, pulmonary embolism, and sleep apnea as independent predictive variables. The nomogram demonstrated good discrimination (C‐index = 0.71) and calibration.

Conclusions

Pulmonary comorbidities and BMI have significant prognostic value in IPF, emphasizing the necessity for consistent screening, assessment, and management of these factors in IPF care. Furthermore, the nomogram‐based staging system showed promising performance in predicting OS and represents an actionable staging system that could potentially improve clinical management in IPF. Further validation of the nomogram is warranted to confirm its utility in clinical practice.

Keywords

body mass indexhypertensionidiopathic pulmonary fibrosisnomogramstaging systemsurvival

Electronic Supplementary Material

Download File(s)
med-2-4-336_ESM.docx (112.2 KB)

References

[1]

O’Connell OJ, Egan JJ. The burden of disease and the need for a simple staging system in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2014;189(7):765–7. https://doi.org/10.1164/rccm.201402-0306ED

Crossref Google Scholar
[2]

Ley B, Ryerson CJ, Vittinghoff E, Ryu JH, Tomassetti S, Lee JS, et al. A multidimensional index and staging system for idiopathic pulmonary fibrosis. Ann Intern Med. 2012;156(10):684–91. https://doi.org/10.7326/0003-4819-156-10-201205150-00004

Crossref Google Scholar
[3]

Caminati A, Lonati C, Cassandro R, Elia D, Pelosi G, Torre O, et al. Comorbidities in idiopathic pulmonary fibrosis: an underestimated issue. Eur Respir Rev. 2019;28(153):190044. https://doi.org/10.1183/16000617.0044-2019

Crossref Google Scholar
[4]

Raghu G, Amatto VC, Behr J, Stowasser S. Comorbidities in idiopathic pulmonary fibrosis patients: a systematic literature review. Eur Respir J. 2015;46(4):1113–30. https://doi.org/10.1183/13993003.02316-2014

Crossref Google Scholar
[5]

Torrisi SE, Ley B, Kreuter M, Wijsenbeek M, Vittinghoff E, Collard HR, et al. The added value of comorbidities in predicting survival in idiopathic pulmonary fibrosis: a multicentre observational study. Eur Respir J. 2019;53(3):1801587. https://doi.org/10.1183/13993003.01587-2018

Crossref Google Scholar
[6]

Lacedonia D, De Pace CC, Rea G, Capitelli L, Gallo C, Scioscia G, et al. Machine learning and BMI improve the prognostic value of GAP index in treated IPF patients. Bioengineering. 2023;10(2):251. https://doi.org/10.3390/bioengineering10020251

Crossref Google Scholar
[7]

Suzuki Y, Mori K, Aono Y, Kono M, Hasegawa H, Yokomura K, et al. Combined assessment of the GAP index and body mass index at antifibrotic therapy initiation for prognosis of idiopathic pulmonary fibrosis. Sci Rep. 2021;11(1):18579. https://doi.org/10.1038/s41598-021-98161-y

Crossref Google Scholar
[8]

Chun FKH, Briganti A, Karakiewicz PI, Graefen M. Should we use nomograms to predict outcome? Eur Urol Suppl. 2008;7(5):396–9. https://doi.org/10.1016/j.eursup.2008.01.011

Crossref Google Scholar
[9]

Shariat SF, Karakiewicz PI, Godoy G, Lerner SP. Use of nomograms for predictions of outcome in patients with advanced bladder cancer. Ther Adv Urol. 2009;1(1):13–26. https://doi.org/10.1177/1756287209103923

Crossref Google Scholar
[10]

Lee W, Lam SK, Zhang Y, Yang R, Cai J. Review of methodological workflow, interpretation and limitations of nomogram application in cancer study. Radiat Med Prot. 2022;3(4):200–7. https://doi.org/10.1016/j.radmp.2022.08.004

Crossref Google Scholar
[11]

Raghu G, Remy‐Jardin M, Myers JL, Richeldi L, Ryerson CJ, Lederer DJ, et al. Diagnosis of idiopathic pulmonary fibrosis. An official ATS/ERS/JRS/ALAT clinical practice guideline. Am J Respir Crit Care Med. 2018;198(5):e44–68. https://doi.org/10.1164/rccm.201807-1255st

Crossref Google Scholar
[12]

Sangani R, Ghio A, Culp S, Patel Z, Sharma S. Combined pulmonary fibrosis emphysema: role of cigarette smoking and pulmonary hypertension in a rural cohort. Int J Chronic Obstr Pulm Dis. 2021;16:1873–85. https://doi.org/10.2147/COPD.S307192

Crossref Google Scholar
[13]

Sangani RG, Ghio AJ, Mujahid H, Patel Z, Catherman K, Wen S, et al. Outcomes of idiopathic pulmonary fibrosis improve with obesity: a rural Appalachian experience. South Med J. 2021;114(7):424–31. https://doi.org/10.14423/SMJ.0000000000001275

Crossref Google Scholar
[14]

Yoon HY, Kim H, Bae Y, Song JW. Smoking status and clinical outcome in idiopathic pulmonary fibrosis: a nationwide study. Respir Res. 2024;25(1):191. https://doi.org/10.1186/s12931-024-02819-w

Crossref Google Scholar
[15]

Becklake MR, Lalloo U. The ‘healthy smoker’: a phenomenon of health selection? Respiration. 1990;57(3):137–44. https://doi.org/10.1159/000195837

Crossref Google Scholar
[16]

van Walraven C, McCudden C, Austin PC. Imputing missing laboratory results may return erroneous values because they are not missing at random. J Clin Epidemiol. 2023;154:65–74. https://doi.org/10.1016/j.jclinepi.2022.12.011

Crossref Google Scholar
[17]

Ross RK, Breskin A, Westreich D. When is a complete‐case approach to missing data valid? The importance of effect‐measure modification. Am J Epidemiol. 2020;189(12):1583–9. https://doi.org/10.1093/aje/kwaa124

Crossref Google Scholar
[18]

Sterne JAC, White IR, Carlin JB, Spratt M, Royston P, Kenward MG, et al. Multiple imputation for missing data in epidemiological and clinical research: potential and pitfalls. BMJ. 2009;338(jun29 1):b2393. https://doi.org/10.1136/bmj.b2393

Crossref Google Scholar
[19]

Behr J, Prasse A, Wirtz H, Koschel D, Pittrow D, Held M, et al. Survival and course of lung function in the presence or absence of antifibrotic treatment in patients with idiopathic pulmonary fibrosis: long‐term results of the INSIGHTS‐IPF registry. Eur Respir J. 2020;56(2):1902279. https://doi.org/10.1183/13993003.02279-2019

Crossref Google Scholar
[20]

Fainberg HP, Oldham JM, Molyneau PL, Allen RJ, Kraven LM, Fahy WA, et al. Forced vital capacity trajectories in patients with idiopathic pulmonary fibrosis: a secondary analysis of a multicentre, prospective, observational cohort. Lancet Digit Health. 2022;4(12):e862–72. https://doi.org/10.1016/S2589-7500(22)00173-X

Crossref Google Scholar
[21]

Patridge EF, Bardyn TP. Research electronic data capture (REDCap). J Med Libr Assoc. 2018;106(1):142–4. https://doi.org/10.5195/JMLA.2018.319

Crossref Google Scholar
[22]

Tibshirani R. Regression shrinkage and selection via the Lasso. J R Stat Soc Series B Stat Methodol. 1996;58(1):267–88. https://doi.org/10.1111/j.2517-6161.1996.tb02080.x

Crossref Google Scholar
[23]

Grambsch PM, Therneau TM. Proportional hazards tests and diagnostics based on weighted residuals. Biometrika. 1994;81(3):515–26. https://doi.org/10.1093/biomet/81.3.515

Crossref Google Scholar
[24]

Turkson AJ, Ayiah‐Mensah F, Nimoh V. Handling censoring and censored data in survival analysis: a standalone systematic literature review. Int J Math Math Sci. 2021;2021:9307475. https://doi.org/10.1155/2021/9307475

Crossref Google Scholar
[25]

Harrell FE, Califf RM, Pryor DB, Lee KL, Rosati RA. Evaluating the yield of medical tests. JAMA. 1982;247(18):2543–6. https://doi.org/10.1001/JAMA.1982.03320430047030

Crossref Google Scholar
[26]

Moons KGM, Altman DG, Reitsma JB, Ioannidis JPA, MacAskill P, Steyerberg EW, et al. Transparent Reporting of a multivariable prediction model for Individual Prognosis or Diagnosis (TRIPOD): explanation and elaboration. Ann Intern Med. 2015;162(1):W1–73. https://doi.org/10.7326/M14-0698

Crossref Google Scholar
[27]

Ley B, Collard HR, King TE. Clinical course and prediction of survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2011;183(4):431–40. https://doi.org/10.1164/rccm.201006-0894ci

Crossref Google Scholar
[28]

Hyldgaard C, Møller J, Bendstrup E. Changes in management of idiopathic pulmonary fibrosis: impact on disease severity and mortality. Eur Clin Respir J. 2020;7(1):1807682. https://doi.org/10.1080/20018525.2020.1807682

Crossref Google Scholar
[29]

Yoon HY, Kim TH, Seo JB, Lee SM, Lim S, Lee HN, et al. Effects of emphysema on physiological and prognostic characteristics of lung function in idiopathic pulmonary fibrosis. Respirology. 2019;24(1):55–62. https://doi.org/10.1111/resp.13387

Crossref Google Scholar
[30]

Kim YS, Jin GY, Chae KJ, Han YM, Chon SB, Lee YS, et al. Visually stratified CT honeycombing as a survival predictor in combined pulmonary fibrosis and emphysema. Br J Radiol. 2015;88(1055):20150545. https://doi.org/10.1259/bjr.20150545

Crossref Google Scholar
[31]

Doubková M, Švancara J, Svoboda M, Šterclová M, Bartoš V, Plačková M, et al. EMPIRE Registry, Czech Part: impact of demographics, pulmonary function and HRCT on survival and clinical course in idiopathic pulmonary fibrosis. Clin Res J. 2018;12(4):1526–35. https://doi.org/10.1111/crj.12700

Crossref Google Scholar
[32]

Zinellu A, Carru C, Pirina P, Fois AG, Mangoni AA. A systematic review of the prognostic significance of the body mass index in idiopathic pulmonary fibrosis. J Clin Med. 2023;12(2):498. https://doi.org/10.3390/jcm12020498

Crossref Google Scholar
[33]

Nishiyama O, Yamazaki R, Sano H, Iwanaga T, Higashimoto Y, Kume H, et al. Fat‐free mass index predicts survival in patients with idiopathic pulmonary fibrosis. Respirology. 2017;22(3):480–5. https://doi.org/10.1111/resp.12941

Crossref Google Scholar
[34]

Prado CM, Gonzalez MC, Heymsfield SB. Body composition phenotypes and obesity paradox. Curr Opin Clin Nutr Metab Care. 2015;18(6):535–51. https://doi.org/10.1097/MCO.0000000000000216

Crossref Google Scholar
[35]

Jensen GL, Cederholm T, Correia MITD, Gonzalez MC, Fukushima R, Higashiguchi T, et al. GLIM criteria for the diagnosis of malnutrition: a consensus report from the global clinical nutrition community. JPEN ‐ J Parenter Enter Nutr. 2019;43(1):32–40. https://doi.org/10.1002/jpen.1440

Crossref Google Scholar
[36]

Shakersain B, Santoni G, Faxén‐Irving G, Rizzuto D, Fratiglioni L, Xu W. Nutritional status and survival among old adults: an 11‐year population‐based longitudinal study. Eur J Clin Nutr. 2016;70(3):320–5. https://doi.org/10.1038/ejcn.2015.109

Crossref Google Scholar
[37]

Richeldi L, du Bois RM, Raghu G, Azuma A, Brown KK, Costabel U, et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med. 2014;370(22):2071–82. https://doi.org/10.1056/NEJMoa1402584

Crossref Google Scholar
[38]

Jouneau S, Kerjouan M, Rousseau C, Lederlin M, Llamas‐Guttierez F, De Latour B, et al. What are the best indicators to assess malnutrition in idiopathic pulmonary fibrosis patients? A cross‐sectional study in a referral center. Nutrition. 2019;62:115–21. https://doi.org/10.1016/j.nut.2018.12.008

Crossref Google Scholar
[39]

Kasprzyk A, Bilmin K, Chmielewska‐Ignatowicz T, Pawlikowski J, Religioni U, Merks P. The role of nutritional support in malnourished patients with lung cancer. In Vivo. 2021;35(1):53–60. https://doi.org/10.21873/invivo.12231

Crossref Google Scholar
[40]

Waxman AB, Elia D, Adir Y, Humbert M, Harari S. Recent advances in the management of pulmonary hypertension with interstitial lung disease. Eur Respir Rev. 2022;31(165):210220. https://doi.org/10.1183/16000617.0220-2021

Crossref Google Scholar
[41]

Nikkho SM, Richter MJ, Shen E, Abman SH, Antoniou K, Chung J, et al. Clinical significance of pulmonary hypertension in interstitial lung disease: a consensus statement from the Pulmonary Vascular Research Institute’s innovative drug development initiative‐Group 3 pulmonary hypertension. Pulm Circ. 2022;12(3):e12127. https://doi.org/10.1002/pul2.12127

Crossref Google Scholar
[42]

Patel NM, Lederer DJ, Borczuk AC, Kawut SM. Pulmonary hypertension in idiopathic pulmonary fibrosis. Chest. 2007;132(3):998–1006. https://doi.org/10.1378/chest.06-3087

Crossref Google Scholar
[43]

Kimura M, Taniguchi H, Kondoh Y, Kimura T, Kataoka K, Nishiyama O, et al. Pulmonary hypertension as a prognostic indicator at the initial evaluation in idiopathic pulmonary fibrosis. Respiration. 2013;85(6):456–63. https://doi.org/10.1159/000345221

Crossref Google Scholar
[44]

Olschewski H, Behr J, Bremer H, Claussen M, Douschan P, Halank M, et al. Pulmonary hypertension due to lung diseases: updated recommendations from the Cologne Consensus Conference 2018. Int J Cardiol. 2018;272S:63–8. https://doi.org/10.1016/j.ijcard.2018.08.043

Crossref Google Scholar
[45]

Waxman A, Restrepo‐Jaramillo R, Thenappan T, Ravichandran A, Engel P, Bajwa A, et al. Inhaled treprostinil in pulmonary hypertension due to interstitial lung disease. N Engl J Med. 2021;384(4):325–34. https://doi.org/10.1056/NEJMoa2008470

Crossref Google Scholar
[46]

Jacob J, Bartholmai BJ, Rajagopalan S, Kokosi M, Maher TM, Nair A, et al. Functional and prognostic effects when emphysema complicates idiopathic pulmonary fibrosis. Eur Respir J. 2017;50(1):1700379. https://doi.org/10.1183/13993003.00379-2017

Crossref Google Scholar
[47]

Kim HJ, Snyder LD, Neely ML, Hellkamp AS, Hotchkin DL, Morrison LD, et al. Clinical outcomes of patients with combined idiopathic pulmonary fibrosis and emphysema in the IPF‐PRO Registry. Lung. 2022;200(1):21–9. https://doi.org/10.1007/s00408-021-00506-x

Crossref Google Scholar
[48]

Sugino K, Ishida F, Kikuchi N, Hirota N, Sano G, Sato K, et al. Comparison of clinical characteristics and prognostic factors of combined pulmonary fibrosis and emphysema versus idiopathic pulmonary fibrosis alone. Respirology. 2014;19(2):239–45. https://doi.org/10.1111/resp.12207

Crossref Google Scholar
[49]

Zhang L, Zhang C, Dong F, Song Q, Chi F, Liu L, et al. Combined pulmonary fibrosis and emphysema: a retrospective analysis of clinical characteristics, treatment and prognosis. BMC Pulm Med. 2016;16(1):137. https://doi.org/10.1186/s12890-016-0300-7

Crossref Google Scholar
[50]

Ozawa Y, Suda T, Naito T, Enomoto N, Hashimoto D, Fujisawa T, et al. Cumulative incidence of and predictive factors for lung cancer in IPF. Respirology. 2009;14(5):723–8. https://doi.org/10.1111/j.1440-1843.2009.01547.x

Crossref Google Scholar
[51]

Vancheri C, Failla M, Crimi N, Raghu G. Idiopathic pulmonary fibrosis: a disease with similarities and links to cancer biology. Eur Respir J. 2010;35(3):496–504. https://doi.org/10.1183/09031936.00077309

Crossref Google Scholar
[52]

Karampitsakos T, Spagnolo P, Mogulkoc N, Wuyts WA, Tomassetti S, Bendstrup E, et al. Lung cancer in patients with idiopathic pulmonary fibrosis: a retrospective multicentre study in Europe. Respirology. 2023;28(1):56–65. https://doi.org/10.1111/resp.14363

Crossref Google Scholar
[53]

Tomassetti S, Gurioli C, Ryu JH, Decker PA, Ravaglia C, Tantalocco P, et al. The impact of lung cancer on survival of idiopathic pulmonary fibrosis. Chest. 2015;147(1):157–64. https://doi.org/10.1378/chest.14-0359

Crossref Google Scholar
[54]

Kim H, Yoo H, Pyo H, Ahn YC, Noh JM, Ju SG, et al. Impact of underlying pulmonary diseases on treatment outcomes in early‐stage non‐small cell lung cancer treated with definitive radiotherapy. Int J Chronic Obstr Pulm Dis. 2019;14:2273–81. https://doi.org/10.2147/COPD.S210759

Crossref Google Scholar
[55]

Vasakova M, Sterclova M, Moğulkoç N, Lewandowska K, Müller V, Hajkova M, et al. Healthy survivor bias in patients with idiopathic pulmonary fibrosis in clinical registries. Eur Respir J. 2021;58(Suppl 65):PA477. https://doi.org/10.1183/13993003.congress-2021.pa477

Crossref Google Scholar
[56]

Vittinghoff E, McCulloch CE. Relaxing the rule of ten events per variable in logistic and Cox regression. Am J Epidemiol. 2007;165(6):710–8. https://doi.org/10.1093/aje/kwk052

Crossref Google Scholar
[57]
D’Agostino RB, Nam BH. Evaluation of the performance of survival analysis models: discrimination and calibration measures. In: Handbook of statistics. Amsterdam: Elsevier; 2003. p. 1–25. https://doi.org/10.1016/s0169-7161(03)23001-7
Crossref
[58]

Topoluk N, Patel JJ. The implications of using BMI alone in outcomes research. Chest. 2022;162(4):e204. https://doi.org/10.1016/j.chest.2022.06.043

Crossref Google Scholar
[59]

Bleeker SE, Moll HA, Steyerberg EW, Donders ART, Derksen‐Lubsen G, Grobbee DE, et al. External validation is necessary in prediction research: a clinical example. J Clin Epidemiol. 2003;56(9):826–32. https://doi.org/10.1016/s0895-4356(03)00207-5

Crossref Google Scholar
[60]

Zhang X, Ren Y, Xie B, Wang S, Geng J, He X, et al. External validation of the GAP model in Chinese patients with idiopathic pulmonary fibrosis. Clin Res J. 2023;17(9):831–40. https://doi.org/10.1111/crj.13564

Crossref Google Scholar
[61]

Lee SH, Kim SY, Kim DS, Kim YW, Chung MP, Uh ST, et al. Predicting survival of patients with idiopathic pulmonary fibrosis using GAP score: a nationwide cohort study. Respir Res. 2016;17(1):131. https://doi.org/10.1186/s12931-016-0454-0

Crossref Google Scholar
Medicine Advances
Volume 2 Issue 4,
December 2024
Pages 336-348
DOI: 10.1002/med4.86
Cite this article:
Mohamed R, Sangani RG, Kamal KM, et al. Development of a local nomogram‐based scoring system for predicting overall survival in idiopathic pulmonary fibrosis: A rural appalachian experience. Medicine Advances, 2024, 2(4): 336-348. https://doi.org/10.1002/med4.86
Metrics & Citations  
Article History
Copyright
Rights and Permissions
Return